Explore the latest news and clinical updates on CAR-T cell therapy for leukemia, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and other subtypes. We cover breakthrough research, regulatory approvals, real-world treatment outcomes, and emerging technologies shaping the future of leukemia care. Our focus includes developments in China and global progress in CAR-T innovation.
The National Comprehensive Cancer Network (NCCN) has released Acute Lymphoblastic Leukemia, Version 2.2026, providing an updated framework for the management of acute lymphoblastic leukemia (ALL). One of the most notable
A multicenter study published in Cytotherapy shows CD19 CAR-T therapy delivers high remission rates and promising long-term survival for B-ALL patients who relapse after allogeneic stem cell transplantation.
At ASH 2025, new data reveals that Inaticabtagene Autoleucel delivers high response rates and durable remissions in adult B-ALL patients who relapse after stem cell transplant.
On November 7, 2025, the National Medical Products Administration (NMPA) officially approved Puzolcabtagene Autoleucel Injection, an independently developed Class I biological drug, for marketing in China for the treatment for
CNCT19 (Inaticabtagene Autoleucel) is the China’s first independently developed CAR T-cell therapy in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). On December 3, 2024, the
CNCT19 is the first approved CAR T-cell therapy in China for the treatment of adult B-ALL.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.